Karen McKerihan, MSN, NP-C
Director of Infusion Services
Colin Edgerton, MD
This activity has been designed to meet the educational needs of rheumatology nurses, nurse practitioners, and physician assistants. Other healthcare providers may also participate.
Learning Objectives and Goals:
Upon completion of this activity, participants should be able to:
- Explain key concepts related to biosimilars such as drug interchangeability, substitution, and data extrapolation
- Analyze current barriers to the use of biosimilars in clinical practice
- Discuss the importance of patient education surrounding biosimilars and the appropriate role of the nurse and advanced practice provider as patient educator as part of the shared decision making process
The Rheumatology Nurses Society is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (Provider No. P0500).
Participants will receive 0.5 hours of continuing nursing contact hours, with 0.5 pharmacotherapeutic contact hours, by completing the education, completing an online evaluation, and receiving a post-test score of 70%.
According to the disclosure policy of RNS, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.
Relationships are abbreviated as follows: E, Educational planning committee; G, Grant/research support recipient; A, Advisor/review panel member; C, Consultant; S, Stock shareholder; SB, Speaker bureau; PE, Promotional event talks; H, Honoraria; O, Other.
Planners, reviewers, and faculty have disclosed no conflicts of interest related to the content of this education, with the exception of the following:
Karen McKerihan, MSN, NP-C, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Janssen/AB.
Colin Edgerton, MD, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: XXX.
Kim Cheramie, MSN, RN-BC, Accredited Provider Program Director, Rheumatology Nurses Society
Scott Kober, MBA, Managing Partner, Excalibur Medical Education
Kevin Lyons, Executive Director of the Rheumatology Nurses Society and Chief Executive Officer of Lyons Den Solutions, LLC
Off-Label Product Disclosure
This activity will not include a discussion of off-label or investigational use of products.
Method of Participation
There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE contact hours for your participation, please complete the post-test (achieving a passing grade of 75% or greater), and program evaluation. Your certificate can be printed immediately.
This activity is supported by an educational grant from Pfizer.
This course is set to expire August 1st, 2023